Clinical Trials - May 16, 2022
Immunicum reports positive Phase II results
Immunicum has announced updated interim results from the ongoing ADVANCE II clinical trial evaluating the company’s lead development program DCP-001, a novel therapeutic option for acute myeloid leukemia (AML) maintenance therapy in patients with measurable residual disease (MRD). The analysis demonstrates the therapeutic potential of DCP-001 to control MRD based on the complete read-out of […]
In a new job - May 6, 2022
Immunicum appoints new Chief Technology Officer
Immunicum has announced the appointment of Leopold Bertea as Chief Technology Officer (CTO), effective as of May 5, 2022. In his role as CTO at Immunicum, Bertea will be driving the build-up of a global manufacturing infrastructure for Immunicum’s lead pipeline program, DCP-001, which is currently progressing through a Phase II clinical study. Additionally, he […]
Clinical Trials - May 4, 2022
Immunicum presents pre-clinical data
Immunicum has announced the publication of a scientific abstract that discloses new preclinical data on DCP-001, the company’s lead clinical candidate, in combination with 5’-azacitidine (5-AZA), a hypomethylating agent, and venetoclax (VEN), a BCL2 inhibitor, in a preclinical setting. The in vivo and in vitro data support the evaluation of DCP-001 as a potential combination […]
Acquisition - January 5, 2022
Immunicum transfers patent rights to Elicera
Immunicum has announced to transfer its patent rights for modified adenovirus (patent US 9,017,672 B2) to Elicera Therapeutics. The patent is currently out-licensed to Elicera and covers a modified adenovirus that improves gene delivery and tumor cell killing efficiency. “We are happy to enable Elicera to strengthen its patent position for its lead program while […]
Clinical Trials - December 3, 2021
Immunicum completes Phase Ib portion of ILIAD study
Immunicum has announced the completion of the Phase Ib portion of the ILIAD study evaluating the company’s off-the-shelf, cell-based immune primer ilixadencel in combination with anti-PD1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda) in different cancer indications. All subjects in the Phase Ib portion have completed the initial follow-up period for safety and response evaluation, with a […]
Collaboration - November 30, 2021
Immunicum and PCI Biotech extend their collaboration
Immunicum and PCI Biotech Holding have announced an extension of their current research collaboration to explore novel cancer vaccination treatments. The companies jointly research the possibility to overcome current hurdles in cancer immunotherapy by introducing tumor independent immune targets into the tumor microenvironment, in combination with vaccination or adoptive immunotherapies. The so-called Tumor Independent Antigen […]
